Michael Strupp

This inventor holds 14 USPTO granted patents and 8 published patent applications and 9 EPO patents. Top assignee: Intrabio Limited. Active years: 2021-2026.

USPTO Granted Patents = 14 (Patent Applications = 8)

% Patents Active = 85.7

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 1.2

ph-index = 2

Forward Citations = 20(Granted Patents)

Location History:

Marchioninistr, DE (2023)
Munich, DE (2021 - 2024)

Company Filing History:

14 out of 18

Intrabio Limited

patents

Years Active: 2021-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12697316 - Combination therapy with acetyl-leucine and miglustat (2026-08-04),

2. 12667550 - Treatment of late-onset neurodegenerative diseases in heterozygous NPC1 gene mutation carriers (2026-06-30),

3. 12433863 - Pharmaceutical compositions and uses directed to lysosomal storage disorders (2025-10-07),

4. 12433862 - Pharmaceutical compositions and uses directed to lysosomal storage disorders (2025-10-07),

5. 12329733 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function (2025-06-17),

6. 12144792 - Therapeutic agents for neurodegenerative diseases (2024-11-19),

7. 12121513 - Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject (2024-10-22),

8. 11998518 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function (2024-06-04),

9. 11690830 - Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject (2023-07-04),

10. 11660279 - Therapeutic agents for treating restless leg syndrome (2023-05-30),

11. 11471434 - Treatment for migraine (2022-10-18),

12. 11400067 - Pharmaceutical compositions and uses directed to lysosomal storage disorders (2022-08-02),

13. 11083718 - Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject (2021-08-10),

14. 10905670 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function (2021-02-02),

Title: Michael Strupp: Innovator in Pharmaceutical Compositions

Introduction

Michael Strupp is a prominent inventor based in Munich, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of lysosomal storage disorders. With a total of 14 patents to his name, Strupp's work is recognized for its innovative approach to complex medical conditions.

Latest Patents

Strupp's latest patents focus on pharmaceutical compositions and their uses directed towards lysosomal storage disorders (LSDs). One of his notable disclosures involves the administration of acetyl-leucine or a pharmaceutically acceptable salt thereof as a treatment for these disorders. This innovative approach aims to provide effective solutions for patients suffering from LSDs, showcasing Strupp's commitment to advancing medical science.

Career Highlights

Throughout his career, Michael Strupp has been associated with Intrabio Limited, a company dedicated to developing treatments for rare diseases. His work at Intrabio has allowed him to collaborate with leading experts in the field, further enhancing his contributions to pharmaceutical innovations.

Collaborations

Strupp has worked alongside Mallory Factor, a fellow innovator in the pharmaceutical industry. Their collaboration has led to advancements in the understanding and treatment of lysosomal storage disorders, highlighting the importance of teamwork in scientific research.

Conclusion

Michael Strupp's contributions to the field of pharmaceuticals, particularly in the treatment of lysosomal storage disorders, demonstrate his innovative spirit and dedication to improving patient outcomes. His work continues to inspire future advancements in medical science.